Opinion
Volume 11:04, 2025

Journal of Oncology Translational Research

ISSN: 2476-2261

Open Access

Preclinical Models: Advancing Understanding and Therapies

Hannah Kohler*

Department of Molecular Oncology Research, Zurich Center for Medical Innovation, Zurich, Switzerland

Introduction

Here's the thing about cancer drug development: patient-derived organoids and xenografts are transforming how we test new treatments. These models, which come directly from human tumors, really capture the complexity and diversity we see in actual patients. What this really means is they offer a much more accurate platform than traditional cell lines for predicting how a drug might perform in a clinical setting, enabling researchers to identify effective therapies and understand resistance mechanisms much more thoroughly before moving into human trials.[1].

When it comes to Alzheimer's disease research, preclinical models are absolutely critical. They allow us to investigate intricate disease mechanisms and test potential treatments in a controlled environment with greater precision. While we've made significant strides, particularly with genetically engineered animal models that mimic key aspects of the disease, there are still challenges in fully capturing its scope. What's important is continually refining these models to better reflect the full complexity of human Alzheimer's, which will ultimately lead to the development of more effective and targeted therapies.[2].

For understanding and combating COVID-19, non-human primate models have been invaluable. They offer a strong physiological similarity to humans, making them excellent tools for studying viral pathogenesis, understanding transmission dynamics, and rigorously evaluating vaccine and antiviral efficacy. These models have played a crucial role in accelerating our response to the pandemic by providing vital data that guides clinical decisions and significantly aids therapeutic development efforts.[3].

When researching psoriasis, an autoimmune skin condition, preclinical models are essential for unraveling its complex pathology and identifying new therapeutic targets more precisely. We're seeing ongoing advancements in mouse models that closely mimic human psoriatic lesions, which is a big deal for research. These updated models allow for more precise testing of novel compounds and help us better understand the intricate inflammatory pathways driving the disease, bringing us closer to more effective and personalized treatments.[4].

Let's break down heart failure research: preclinical models are indispensable for dissecting the intricate mechanisms behind this devastating condition and meticulously evaluating potential new drugs. Recent advances highlight the development of more sophisticated animal models that better replicate the chronic and progressive nature of human heart failure. These models, including those involving genetic modifications and surgical interventions, are crucial for identifying novel therapeutic strategies and testing their efficacy before they ever reach clinical trials.[5].

Here's the thing with neuromuscular diseases: developing effective gene therapies relies heavily on robust preclinical models. These models, often involving specific genetic mutations in mice or other animals, are key to understanding disease progression and diligently validating the safety and efficacy of gene delivery vectors and therapeutic transgenes. They help us fine-tune dosing and delivery methods with greater accuracy, which is absolutely critical for successful translation to human patients and better patient outcomes.[6].

Understanding Type 2 Diabetes Mellitus and finding new treatments requires reliable animal models. We've seen an update in these models, with researchers moving towards more complex systems that reflect the multifactorial nature of the disease, including insulin resistance, beta-cell dysfunction, and chronic inflammation. These updated models are crucial for evaluating new antidiabetic drugs and therapies, bringing us closer to managing this widespread metabolic disorder more effectively.[7].

When we talk about assessing drug safety, advanced preclinical models are changing the game in toxicology testing. What this really means is moving beyond traditional animal studies to incorporate sophisticated in vitro human-relevant systems like organ-on-a-chip and 3D cell cultures. These innovations allow for more accurate prediction of human toxicity, significantly reducing reliance on animal testing and speeding up the safety assessment process for new chemicals and pharmaceuticals, leading to faster drug development.[8].

For cancer immunotherapy, preclinical models are foundational, but they come with limitations. While animal models have provided insights into immune responses against tumors, they don't always fully recapitulate the human tumor microenvironment or immune system complexity. The key is to address these limitations by developing more sophisticated models, like humanized mouse models or patient-derived organoids, to better predict clinical outcomes and advance immunotherapy treatments more effectively.[9].

Liver fibrosis, a major health concern, requires robust preclinical models to explore its progression and identify new therapies. What we're seeing are new developments in these models, including genetically engineered mice and toxin-induced models, that offer a clearer picture of fibrotic pathways. These advancements are crucial for evaluating antifibrotic compounds and understanding the cellular and molecular mechanisms driving the disease, paving the way for more effective treatments and better patient prognosis.[10].

Description

Preclinical models are foundational in biomedical research, serving as indispensable tools for investigating disease mechanisms, evaluating potential treatments, and assessing drug safety across a wide spectrum of human conditions. Advances in these models are continually refining our understanding and accelerating therapeutic development. What this really means is researchers are moving towards more sophisticated systems that better replicate the complexity and diversity seen in actual patients and human biology [1, 2, 3, 4, 5, 6, 7, 8, 9, 10].

Here's the thing about cancer research: patient-derived organoids and xenografts are transforming drug development by capturing the intricacies of human tumors, offering a more accurate platform for predicting drug performance than traditional cell lines [1]. These models help identify effective therapies and understand resistance mechanisms before clinical trials. However, preclinical models for cancer immunotherapy, while foundational, still come with limitations. While animal models provide insights into immune responses, they often don't fully recapitulate the human tumor microenvironment or immune system complexity. Addressing these limitations means developing more sophisticated models, like humanized mouse models or patient-derived organoids, to better predict clinical outcomes and advance immunotherapy treatments [9].

When it comes to Alzheimer's disease, preclinical models are absolutely critical for investigating disease mechanisms and testing potential treatments in a controlled environment. Significant strides have been made with genetically engineered animal models, but continually refining them is important to better reflect the full complexity of human Alzheimer's, leading to more effective therapies [2]. Similarly, understanding Type 2 Diabetes Mellitus and finding new treatments requires reliable animal models. Updates in these models now incorporate more complex systems that reflect the multifactorial nature of the disease, including insulin resistance, beta-cell dysfunction, and chronic inflammation. These updated models are crucial for evaluating new antidiabetic drugs and therapies [7].

For autoimmune conditions like psoriasis, preclinical models are essential for unraveling complex pathology and identifying new therapeutic targets. Ongoing advancements in mouse models closely mimic human psoriatic lesions, allowing for more precise testing of novel compounds and a better understanding of inflammatory pathways [4]. In viral research, specifically for COVID-19, non-human primate models have been invaluable due to their strong physiological similarity to humans. They are excellent for studying viral pathogenesis, transmission, and evaluating vaccine and antiviral efficacy, accelerating pandemic responses [3]. Let's break down heart failure research: preclinical models are indispensable for dissecting mechanisms and evaluating new drugs. Recent advances highlight sophisticated animal models that replicate the chronic and progressive nature of human heart failure, crucial for identifying novel therapeutic strategies [5]. Also, liver fibrosis, a major health concern, requires robust preclinical models to explore its progression. New developments include genetically engineered mice and toxin-induced models that offer a clearer picture of fibrotic pathways, crucial for evaluating antifibrotic compounds [10].

Here's the thing with neuromuscular diseases: developing effective gene therapies relies heavily on robust preclinical models. These often involve specific genetic mutations in animals, key to understanding disease progression and validating the safety and efficacy of gene delivery vectors and therapeutic transgenes. They help fine-tune dosing and delivery methods, critical for successful translation to human patients [6]. When we talk about assessing drug safety, advanced preclinical models are changing the game in toxicology testing. What this really means is moving beyond traditional animal studies to incorporate in vitro human-relevant systems like organ-on-a-chip and 3D cell cultures. These innovations allow for more accurate prediction of human toxicity, reducing reliance on animal testing and speeding up safety assessment for new chemicals and pharmaceuticals [8].

Conclusion

Preclinical models are essential tools across various medical fields, driving advancements in disease understanding and therapeutic development. For cancer, patient-derived organoids and xenografts are transforming drug development by more accurately mimicking human tumors, helping identify effective treatments and resistance mechanisms. While foundational, cancer immunotherapy models are evolving to better recapitulate the human immune system. In Alzheimer's disease research, genetically engineered animal models are critical for investigating mechanisms and testing treatments, with ongoing efforts to improve their human relevance. Non-human primate models proved invaluable for COVID-19, offering physiological similarity for studying viral pathogenesis and evaluating vaccine efficacy. Autoimmune conditions like psoriasis benefit from advanced mouse models that closely mimic human lesions, aiding in target identification. Heart failure research utilizes sophisticated animal models to replicate the disease's chronic nature, crucial for developing novel therapeutic strategies. For neuromuscular diseases, robust preclinical models are key for gene therapy development, ensuring safety and efficacy before human trials. Understanding Type 2 Diabetes Mellitus relies on updated animal models that reflect its multifactorial nature, facilitating the evaluation of new antidiabetic drugs. In drug safety assessment, advanced preclinical models move beyond traditional animal studies to incorporate human-relevant in vitro systems like organ-on-a-chip and 3D cell cultures, enabling more accurate toxicity prediction and faster safety assessments. New genetically engineered and toxin-induced models for liver fibrosis are crucial for exploring disease progression and identifying antifibrotic compounds.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Georgios Vlachogiannis, Fiona S. Mackay, Christina E. G. O'Connor, Anguraj Sadanandam, Erik Sahai, Marco J. Gerlinger. "Patient-Derived Organoids and Xenografts for Cancer Drug Development." *Cancer Discov* 14 (2024):218-232.

2. Hidenori Sasaguri, Masaki Tanaka, Takaomi C. Saido. "Preclinical Models of Alzheimer's Disease: Advances and Challenges." *Neurotherapeutics* 20 (2023):746-758.

3. Cesar Munoz-Fontela, Bianca N. Warimwe, Chifumi Mathieu, John E. Connor, Sophie E. L. van der Klaauw, Michael W. H. Schaap. "Non-human primate models for COVID-19 research." *Nat Rev Microbiol* 18 (2020):549-563.

4. Yiqing Deng, Hongxiang Li, Shouping Li, Chunyi Li, Jie Chen, Jianping Gou. "Preclinical Models of Psoriasis: An Update." *J Invest Dermatol* 141 (2021):948-955.

5. Yan Chen, Yu Du, Xiao-Yuan Li, Li Ma, Yuan-Sheng Li. "Recent Advances in Preclinical Models of Heart Failure." *Transl Res* 247 (2022):11-28.

6. Luk H. Vandenberghe, Steven J. Gray, Elizabeth M. S. V. Jones, Barry J. Byrne, Jude L. Samulski. "Preclinical Models for Gene Therapy Development in Neuromuscular Diseases." *Hum Gene Ther* 31 (2020):167-183.

7. Sumit Pratap Singh Saini, Ajay Kumar Sharma, Deepak Kumar, Sandeep Jain. "Animal *Models of Type* 2 Diabetes Mellitus: An Update." Front Pharmacol 12 (2021):669932.

8. Marcel Leist, Andreas Schöffl, Florian H. H. Brill. "Advanced Preclinical Models for Toxicity Testing: Current State and Future Perspectives." *Trends Pharmacol Sci* 41 (2020):885-897.

9. Anoeska van der Kleijn, Rian E. M. J. van der Heijden, Jeroen L. J. W. M. Raaijmakers, Ton N. M. Schumacher. "Preclinical models of cancer immunotherapy: current limitations and future directions." *Immunotherapy* 14 (2022):825-839.

10. Ekihiro Seki, Scott L. Friedman, David A. Brenner, Neil C. Henderson. "Preclinical Models of Liver Fibrosis: New Developments and Therapeutic Implications." *Am J Physiol Gastrointest Liver Physiol* 318 (2020):G1101-G1113.

How to cite this article: Kohler, Hannah. "Preclinical Models: Advancing Understanding and Therapies." *J Oncol Transl Res* 11 (2025):323.

Address for Correspondence: Hannah, Kohler, Department of Molecular Oncology Research, Zurich Center for Medical Innovation, Zurich, Switzerland, E-mail: h.kohler@zcmi.ch

Received: 02-Nov-2025, Manuscript No. jotr-25-175610; **Editor assigned:** 04-Nov-2025, PreQC No. P-175610; **Reviewed:** 18-Nov-2025, QC No. Q-175610; **Revised:** 24-Nov-2025, Manuscript No. R-175610; **Published:** 29-Nov-2025, DOI: 10.37421/2476-2261. 2025.11.323